Overarching recommendations for improved access to generic and biosimilar medicines in the hospital setting

Improving healthcare delivery in hospitals by optimized utilization of medicines

A digital future for value added medicines

Calls to action to improve access to value added medicines

Case Studies for Value Added Medicines. Unlocking the potential of patient-centric continuous innovation

Addressing medicine shortages in Europe

Position paper

Reading list

Commentary + EIU document

2017 Market Review – Biosimilar Medicines Markets – Policy Overview

Value Added Medicines: Time to Adjust the HTA Decision Frameworks

Global Healthcare Trends and Outlook

The Impact of Biosimilar Competition in Europe